Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Non-Current Assets (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Non-Current Assets for 6 consecutive years, with $83.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 59.1% to $83.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $298.9 million, a 42.43% increase, with the full-year FY2025 number at $83.1 million, up 59.1% from a year prior.
  • Non-Current Assets was $83.1 million for Q4 2025 at Lexicon Pharmaceuticals, roughly flat from $83.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $83.4 million in Q3 2025 to a low of $51.9 million in Q1 2025.
  • A 3-year average of $60.1 million and a median of $52.9 million in 2023 define the central range for Non-Current Assets.
  • Biggest YoY gain for Non-Current Assets was 59.1% in 2025; the steepest drop was 1.34% in 2025.
  • Lexicon Pharmaceuticals' Non-Current Assets stood at $52.9 million in 2023, then dropped by 1.24% to $52.2 million in 2024, then soared by 59.1% to $83.1 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Non-Current Assets are $83.1 million (Q4 2025), $83.4 million (Q3 2025), and $80.5 million (Q2 2025).